Formycon and Zydus sign exclusive agreement for FYB206 supply
Formycon and Zydus Lifesciences have entered an exclusive licensing and supply agreement for FYB206, a biosimilar of MSD’s Keytruda (Pembrolizumab),…
Formycon and Zydus Lifesciences have entered an exclusive licensing and supply agreement for FYB206, a biosimilar of MSD’s Keytruda (Pembrolizumab),…
Biogen has received a notice of compliance (NOC) from Health Canada for Zurzuvae (zuranolone), a neuroactive steroid (NAS), as a treatment…
Roche has received approval from the European Commission (EC) for its humanised monoclonal antibody Gazyva/Gazyvaro (obinutuzumab) along with mycophenolate mofetil…
New York City-based tech company Inductive Bio has secured up to $21m from the US Advanced Research Projects Agency for…
Viatris has signed definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815m. Viatris…
Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa therapy.…
Takeda and Innovent have closed their global partnership for next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, following the fulfilment…
Formosa Pharmaceuticals and Rxilient Medical have signed an exclusive licensing agreement for the commercialisation of Byqlovi, clobetasol propionate ophthalmic suspension,…
Eli Lilly and Company has received approval from the US Food and Drug Administration (FDA) for the expanded use of…
AGC Biologics is set to expand its Cell Line Development Centre of Excellence through a partnership with ATUM for integrating…